Search Results
Your search for early matches 10016 pages
Showing 2351 - 2400Goal-Focused Emotion-Regulation Therapy for Young Adult Testicular Cancer Survivors
Psychological therapy may reduce adverse biobehavioral effects of testicular cancer in young adult survivors, according to a pilot study published by Hoyt et al in the American Journal of Men’s Health. Biobehavior is the interaction of biologic processes and behavior. The recently published...
Breast Cancer Research Foundation®, Conquer Cancer, and ASCO Celebrate 20th Year of Collaboration
2021 marks the 20th year of collaboration between ASCO; Conquer Cancer®, the ASCO Foundation; and the Breast Cancer Research Foundation® (BCRF). BCRF’s pivotal support during the past 2 decades has been critical to both organizations’ shared achievements in funding breakthroughs in breast cancer...
Reduction in Ipsilateral Recurrence Risk With Radiotherapy vs Observation After Lumpectomy for Good-Risk DCIS
In an analysis of long-term outcomes from the phase III NRG/RTOG 9804 trial reported in the Journal of Clinical Oncology, Beryl McCormick, MD, of Memorial Sloan Kettering Cancer Center, and colleagues found that whole-breast irradiation vs observation was associated with a reduced risk of all and...
Neoadjuvant Atezolizumab Under Study in Mesothelioma
Neoadjuvant atezolizumab combined with pemetrexed and cisplatin, with maintenance atezolizumab, proved to be safe and feasible, offering a hint of benefit in patients with resectable pleural mesothelioma, in a small multicenter study presented at the International Association for the Study of Lung...
The Wistar Institute Appoints Italo Tempera, PhD, as Associate Director for Cancer Research Career Enhancement
The Wistar Institute has announced the appointment of Italo Tempera, PhD, as Associate Director for Cancer Research Career Enhancement at the Institute’s Cancer Center. Dr. Tempera, who is also Associate Professor in the Gene Expression & Regulation Program, will lead the educational mission of ...
Roswell Park and University of Chicago Medicine Comprehensive Cancer Centers Awarded Nearly $9M for Ovarian Cancer Research
For years, scientists at Roswell Park Comprehensive Cancer Center and the University of Chicago Medicine Comprehensive Cancer Center have devoted themselves to research to better understand ovarian cancer. Now, teams of researchers from these two leading centers are combining efforts after together ...
Expert Point of View: Omid Hamid, MD
“The U.S. Food and Drug Administration is currently examining pembrolizumab for the adjuvant treatment of stage IIB and IIC melanoma; if approved, we would be introducing immunotherapy earlier in the patient journey,” commented invited discussant Omid Hamid, MD (@OmidHamidMD), who was an...
Adjuvant Pembrolizumab Shows Efficacy in High-Risk Stage II Melanoma in Adults and Children Older Than 12
Adjuvant pembrolizumab reduced the risk of recurrence in adults and children older than age 12 with high-risk stage II (AJCC 8th edition, stage IIB/IIC) melanoma vs placebo, according to a late-breaking interim analysis of the phase III KEYNOTE-716 trial, presented during the European Society for...
Study Shows Pembrolizumab Plus Chemotherapy Improves Survival in Advanced Cervical Cancer
The addition of pembrolizumab to chemotherapy prolonged survival in recurrent, persistent, or metastatic cervical cancer, according to the results of the first interim analysis of the KEYNOTE-826 trial, presented at a Presidential Symposium during the European Society for Medical Oncology (ESMO)...
Expert Point of View: Monica Arnedos, MD, PhD
Monica Arnedos, MD, PhD, Head of the Breast Cancer Research Program at the Institut Bergonié, Bordeaux, France, commented on the study findings on extended treatment with letrozole. “We cannot ignore the results of the GIM4 trial.1 It provides additional strong evidence to support extended...
Phase III Trial Supports Adjuvant Endocrine Therapy for 7 Years in Early-Stage Breast Cancer
For patients with early-stage hormone receptor–positive breast cancer, extending the duration of letrozole after tamoxifen—for up to 8 years of total endocrine therapy—significantly improved invasive disease–free survival over the standard 5 or so years, according to the final analysis of the...
Oncology Care Remains Under Strain in the Ongoing COVID-19 Pandemic
The resurging COVID-19 pandemic has reawakened challenges for patients and physicians—ones we all hoped were over—and presented stressful situations for patients and providers. Hospitals in some states, particularly those with lower vaccination rates, have faced levels of urgent illness that have...
Expert Point of View: Shanu Modi, MD
Shanu Modi, MD, of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, New York, called the DESTINY-Breast03 results,1 which showed a highly significant benefit for fam-trastuzumab deruxtecan-nxki (T-DXd) over trastuzumab emtansine (T-DM1), “unprecedented.” She suggested they...
DESTINY Breast03 Trial Supports Second-Line Use of T-DXd in Metastatic HER2-Positive Breast Cancer
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) may become a new option as a second-line treatment of patients with HER2-positive unresectable or metastatic breast cancer, based on results from the global phase III DESTINY-Breast03 trial. These findings were presented by Javier...
Effect of Chronic Stress on Treatment Completion and Survival Outcomes in Patients With Breast Cancer
Elevated allostatic load was associated with a lower likelihood of completing chemotherapy and a lower overall survival rate in patients with lymph node–positive or high-risk lymph node–negative HER2-negative breast cancer, according to results presented by Samilia Obeng-Gyasi, MD, MPH, at the 14th ...
Francis S. Collins, MD, PhD, to Step Down as Director of the National Institutes of Health
On October 5, Francis S. Collins, MD, PhD, announced his decision to end his tenure as Director of the National Institutes of Health (NIH) by the end of the year. Dr. Collins is the longest-serving presidentially appointed NIH Director, having served three U.S. presidents over more than 12 years....
Franco M. Muggia, MD, Internationally Regarded Chemotherapy Pioneer, Dies at 85
Today’s life-saving chemotherapeutics originated from the vision and indefatigable work of pioneers in the field whose unwavering vision challenged the status quo. One such pioneer was Franco M. Muggia, MD, who, in a career lasting more than 50 years, had a hand in the development of some of the...
A Guide to End-of-Life Care by a Veteran in Hospice
Given that death is a certain outcome in life, we seek the best way out as possible. What is a good death? According to Jeff Spiess, MD, author of the book Dying With Ease: A Compassionate Guide to Making Wiser End-of-Life Decisions, a good death is one in which pain and suffering are minimized and ...
Glancing Back and Looking Forward in the Fight Against Cancer
“I vividly remember watching television with my older sister, Suzy, and marveling at President Nixon’s signing of the National Cancer Act in December 1971, and thinking ‘for me, this was like a man going to the moon,’” writes Nancy G. Brinker in the foreword to the recently published Centers of the ...
How ASCO Is Expanding Its Commitment to Diversity and Equity in Cancer Care
Ensuring equitable cancer care for every patient, everywhere has been embedded into ASCO’s mission statement since the Society’s inception nearly 60 years ago. Nevertheless, events of the past year, including the ongoing COVID-19 pandemic, which has disproportionally impacted minority communities, ...
Study Finds Medicaid Expansion May Be Associated With Decrease in Early Lung Cancer Mortality
Medicare expansion under the Affordable Care Act may have improved outcomes for patients with lung cancer, the leading cause of cancer death in the United States, according to data presented at the 2021 ASCO Quality Care Symposium.1 The National Cancer Database analysis of nearly 12,000 patients...
Resurgence of COVID-19 Infection in a Large Highly Vaccinated U.S. Health System Workforce
In a letter to the editor in The New England Journal of Medicine, Jocelyn Keehner, MD, of the University of California San Diego Health (UCSDH), and colleagues describe a marked resurgence of COVID-19 infections among fully vaccinated workers in the UCSDH workforce in July 2021.1 The resurgence...
Tackling a Growing Need: Options After CAR T-Cell Therapy for Lymphoma
For aggressive B-cell lymphomas, chimeric antigen receptor (CAR) T-cell therapy saves lives, but relapse remains common, and a second-line standard of care is lacking. During the 2021 Pan Pacific Lymphoma Conference, Grzegorz (Greg) S. Nowakowski, MD, Professor of Medicine and Oncology, Lymphoma...
Emily K. Bergsland, MD: Specializing in Neuroendocrine Tumors, With a Broad Focus on Collaborative Research
Gastrointestinal oncologist Emily K. Bergsland, MD, was born and spent her formative years in La Crosse, Wisconsin, situated on the banks of the Mississippi River. “No one in my family was in the medical field; however, both my parents valued higher education. In fact, when I was in high school, my ...
Adding Value to Clinical Decision-Making in Nonmetastatic Castration-Resistant Prostate Cancer
Several recent investigations have led to the U.S. Food and Drug Administration (FDA) approval of novel antiandrogens to treat nonmetastatic castration-resistant prostate cancer. Yet, this work has not addressed the treatment of nonmetastatic hormone-sensitive biochemically recurrent prostate...
Does a Longer Interval Before Surgery Among Patients With Locally Advanced Rectal Cancer Lead to Worse Survival?
In an Italian retrospective cohort study reported in JAMA Surgery, Deidda et al found that a longer vs shorter delay to surgery among patients with locally advanced rectal cancer with minor or no pathologic response to neoadjuvant chemoradiotherapy was associated with significantly poorer overall...
Adjuvant Atezolizumab Following Adjuvant Chemotherapy for Resected Stage IB to IIIA NSCLC
In the phase III IMpower010 trial reported in The Lancet, Enriqueta Felip, MD, and colleagues found that the use of adjuvant atezolizumab after adjuvant platinum-based chemotherapy significantly improved disease-free survival vs best supportive care in patients with resected stage II to IIIA...
A Look at Tomorrow’s CAR T-Cell Therapy Today
Some of the most impressive data on chimeric antigen receptor (CAR) T-cell therapy have come from studies conducted in China. Attendees at the 2021 Pan Pacific Lymphoma Conference heard from one of the leading Chinese investigators, Peihua (Peggy) Lu, MD, of Lu Daopei Hospital, who described the...
Factors Associated With Early Discontinuation of Endocrine Therapy for Ductal Carcinoma in Situ
In an analysis from the NRG Oncology/NSABP B-35 trial reported in the Journal of Clinical Oncology, N. Lynn Henry, MD, PhD, and colleagues identified toxicity and patient-reported outcome factors associated with early discontinuation of adjuvant endocrine therapy in women with ductal carcinoma in...
Two Studies Show Health-Care Costs May Impact Follow-up Care After Cancer Screening
Eleven years ago this month, the scans and exams that hold the most power to spot the early signs of cancer became available for free to many American adults through the passing of the Affordable Care Act. Now, two new studies show that when those screening tests reveal potentially troubling signs, ...
Study Finds Genetic Predisposition to Higher Lymphocyte Production May Lead to Higher ALL Risk
Research published by Kachuri et al in the American Journal of Human Genetics reveals that children born with a genetic predisposition to produce more lymphocytes—particularly in relation to other types of white blood cells—may be at a higher risk of developing acute lymphoblastic leukemia (ALL)....
Leticia Nogueira, PhD, MPH, on the Association of Medicaid Expansion and Early Mortality Following Lung Cancer Surgery
Leticia Nogueira, PhD, MPH, of the American Cancer Society, discusses results from a study designed to evaluate the impact of Medicaid expansion under the Affordable Care Act (ACA). In Medicaid-expansion states, mortality among patients after lung cancer surgery decreased from 2.4% before the ACA...
Extended Adjuvant Letrozole After Tamoxifen in Postmenopausal Women With Early-Stage Breast Cancer: GIM4
In the Italian phase III GIM4 trial reported in The Lancet Oncology, Lucia Del Mastro, MD, and colleagues found that 5 years vs 2 to 3 years of adjuvant letrozole significantly prolonged invasive disease–free survival in postmenopausal women with early-stage breast cancer who had already completed...
Hepatectomy With or Without Adjuvant mFOLFOX6 for Liver-Only Metastatic Colorectal Cancer: Disease-Free and Overall Survival
In the Japanese phase II/III JCOG0603 trial reported in the Journal of Clinical Oncology, Kanemitsu et al found that the addition of adjuvant mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) to hepatectomy improved disease-free survival in patients with liver-only metastatic colorectal cancer;...
Risk of Pancreatic Cancer Associated With Germline ATM Pathogenic Variants
In a multicenter cohort study reported in JAMA Oncology, Hsu et al found that among pancreatic cancer kindreds, individuals with germline ATM pathogenic variants had a sixfold increased risk of developing pancreatic cancer vs noncarriers of pathogenic variants. Study Details The study involved data ...
ACS Names Elvan ‘Ellie’ Daniels, MD, MPH, Senior Vice President of Extramural Discovery Science
The American Cancer Society (ACS) recently announced that Elvan “Ellie” Daniels, MD, MPH, has been appointed Senior Vice President of Extramural Discovery Science after serving as the interim lead since April 1, 2021. She has also served as a member of the ACS Office of Cancer Research and...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Brunei Darussalam
With a population under half a million people, Brunei Darussalam is a small equatorial nation in Southeast Asia. Bordered by the South China Sea on the north, Brunei Darussalam is surrounded on all other sides by Malaysia, which separates the nation into two noncontiguous parts. Nearly two-thirds...
Paradox Between Cost and Hematopoietic Cell Transplant Rate in Latin America
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Gregorio Jaimovich, MD, Director of the Bone Marrow Transplant Program at Favaloro University Hospital in Buenos Aires. Distinguished expert on radiation therapy and bone...
Gastrointestinal Oncologist Katherine Van Loon, MD, MPH: A Pioneer in Global Oncology
Katherine Van Loon, MD, MPH, was raised in Miami, until the age of 12, and then her family relocated to Atlanta, where she spent her junior and high school years. “If you ask my parents about my decision to become a doctor, they will say I first declared it at age 5. Nobody knew how that idea came...
IASLC Announces Lifetime Achievement Awards
In conjunction with the 2021 World Conference on Lung Cancer, the International Association for the Study of Lung Cancer (IASLC) presented the following lifetime achievement awards. Paul A. Bunn, Jr, Scientific Award David Carbone, MD, PhD, received the Paul A. Bunn, Jr, Scientific Award. This...
New Evidence Drives Need for Revised Guideline on Hormone-Sensitive Advanced Breast Cancer
A recently updated ASCO guideline offers both new and revised guidance on the treatment of hormone receptor–positive, HER2-negative metastatic breast cancer.1 “ASCO regularly updates its guidelines to make sure everything is current and valuable for oncologists and patients. About a year ago,...
Minnesota Senator Amy Klobuchar Announces Breast Cancer Diagnosis
On September 10, 2021, Senator Amy Klobuchar (D-MN) released the following statement: “I wanted to share an update about my health. In February of this year, doctors at Mayo Clinic found small white spots called calcifications during a routine mammogram. After this was discovered, I had a biopsy...
Building a ‘Better Normal’ of Oncology Care to Strengthen Global Health Security After the COVID-19 Pandemic
During the opening session of the 2021 ASCO Annual Meeting, Julio Frenk, MD, PhD, MPH, President of the University of Miami, gave a riveting presentation in which he described the devastating effects of the global COVID-19 pandemic on patients with cancer as well as on fragile and fragmented...
Saad Z. Usmani, MBA, MD, on Multiple Myeloma: Updated Results From the CARTITUDE-1 Study of Ciltacabtagene Autoleucel
Saad Z. Usmani, MBA, MD, of the Levine Cancer Institute, discusses new data on the CAR T-cell therapy ciltacabtagene autoleucel, a single infusion of which yielded early, deep, and durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma (Oral Abstract MM-119).
Expert Point of View: Gordon Cook, MBChB, PhD and Sagar Lonial, MD
The OPTIMUM/MUKnine1 and FORTE2 updates were discussed at the 2021 ASCO Annual Meeting by Gordon Cook, MBChB, PhD, Clinical Director of the National Institute for Health Research In Vitro Diagnostics Cooperative and the Clinical Trials Unit in Hematology of the University of Leeds, United Kingdom....
Myeloma Trial Updates: Focus on High-Risk Patients and Measurable Residual Disease Negativity
Newly diagnosed patients with multiple myeloma deemed at high risk for disease progression may achieve sustained measurable residual disease (MRD) negativity with newer regimens and transplantation, and this may translate into longer progression-free survival. That’s the key take-away message from...
PEACE-1 and STAMPEDE Trials: Abiraterone Acetate Plus Prednisolone in Prostate Cancer
A novel combination of well-known drugs may prolong survival in patients with prostate cancer, according to late-breaking research presented at the European Society for Medical Oncology (ESMO) Congress 2021. The PEACE-1 and STAMPEDE studies found that the addition of abiraterone acetate plus...
Adoptive Cell Therapy May Soon Be Available for Patients With Melanoma
Oncologists who treat patients with melanoma will need to become familiar with another immunotherapy approach. For refractory metastatic disease, adoptive cell therapy is on the horizon. “Adoptive cell therapy will offer additional hope for our patients with melanoma. We’ll likely be seeing this...
ASCO 2021: Roundup of Studies You May Have Missed
As ASCO Annual Meeting attendees know by now, clinicians don’t have to be at McCormick Place to hear practice-changing findings and forward-looking advances in the field of oncology. Interesting content was no exception at the 2021 conference, so in addition to covering the biggest news from the...
Putting Radiotherapy to Best Use With CAR T-Cell Therapy in Lymphoma
The integration of radiation therapy into chimeric antigen receptor (CAR) T-cell therapy may improve outcomes for patients with relapsed or refractory lymphoma, according to Charles A. Enke, MD, Professor and the Bill Bures and Jerry Pabst Chair in Radiation Oncology at the Fred and Pamela Buffett...
